Thinking Long-Term: Data-Driven Decisions about PrEP
Premiere Date: Tuesday, October 26, 2021This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, October 26, 2022
Note: Credit Is No Longer Available
 | David Alain Wohl, MD (Moderator) Professor of Medicine Institute of Global Health and Infectious Diseases Site Leader, Global Infectious Diseases Clinical Trials Unit, Chapel Hill Site The University of North Carolina (UNC) at Chapel Hill School of Medicine Chapel Hill, NC |
 | Margot Savoy, MD, MPH, FAAFP, FABC, CPE, CMQ, FAAPL Associate Professor Department of Family and Community Medicine Lewis Katz School of Medicine at Temple University Philadelphia, PA |
When making treatment decisions regarding PrEP, it is important that clinicians consider the long-term impact on bone health, lipids, and renal dysfunction. This includes the need for education on data comparing the safety and efficacy of emtricitabine and tenofovir disoproxil fumarate (F/TDF) and emtricitabine and tenofovir alafenamide (F/TAF) in order to facilitate data-driven decisions about PrEP.
This CME Outfitters webcast will feature expert faculty discussing clinical trial outcomes and how to apply them to treatment decision-making in order to improve clinical knowledge, confidence, and performance for utilizing PrEP.
At the end of this CE activity, participants should be able to:
- Apply clinical trial outcomes to treatment decision-making, considering long-term impact on bone health, lipids, and renal dysfunction.
Supported by an educational grant from Gilead Sciences, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists
Note to Nurse Practitioners:
Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wohl reports that he receives research support and grants from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Dr. Savoy has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WCV-044-102621-47
